Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2003 5
2004 1
2005 7
2006 2
2007 4
2008 7
2009 5
2010 11
2011 11
2012 6
2013 7
2014 10
2015 12
2016 5
2017 2
2018 3
2019 4
2020 4
2021 6
2022 3
2023 5
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

106 results

Results by year

Filters applied: . Clear all
Page 1
Molecular Pathways: Fatty Acid Synthase.
Jones SF, Infante JR. Jones SF, et al. Clin Cancer Res. 2015 Dec 15;21(24):5434-8. doi: 10.1158/1078-0432.CCR-15-0126. Epub 2015 Oct 30. Clin Cancer Res. 2015. PMID: 26519059 Review.
Everolimus in Breast Cancer: The Role of the Pharmacist.
Dorris JR 3rd, Jones S. Dorris JR 3rd, et al. Among authors: jones s. Ann Pharmacother. 2014 Sep;48(9):1194-1201. doi: 10.1177/1060028014542415. Epub 2014 Jul 9. Ann Pharmacother. 2014. PMID: 25007922 Review.
A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors.
Bauer TM, Moore KN, Rader JS, Simpkins F, Mita AC, Beck JT, Hart L, Chu Q, Oza A, Tinker AV, Imedio ER, Kumar S, Mugundu G, Jenkins S, Chmielecki J, Jones S, Spigel D, Fu S. Bauer TM, et al. Among authors: jones s. Target Oncol. 2023 Jul;18(4):517-530. doi: 10.1007/s11523-023-00965-7. Epub 2023 Jun 6. Target Oncol. 2023. PMID: 37278879 Free PMC article. Clinical Trial.
Safety, tolerability, and pharmacokinetics of Aurora kinase B inhibitor AZD2811: a phase 1 dose-finding study in patients with advanced solid tumours.
Johnson ML, Wang JS, Falchook G, Greenlees C, Jones S, Strickland D, Fabbri G, Kennedy C, Elizabeth Pease J, Sainsbury L, MacDonald A, Schalkwijk S, Szekeres P, Cosaert J, Burris H 3rd. Johnson ML, et al. Among authors: jones s. Br J Cancer. 2023 May;128(10):1906-1915. doi: 10.1038/s41416-023-02185-2. Epub 2023 Mar 4. Br J Cancer. 2023. PMID: 36871042 Free PMC article. Clinical Trial.
Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Laboratory Reference Ranges and Testing Intervals Work Group.
Spira AI, Stewart MD, Jones S, Chang E, Fielding A, Richie N, Wood LS, Thompson MA, Jones L, Nair A, Mahal BA, Gerber DE. Spira AI, et al. Among authors: jones s. Clin Cancer Res. 2021 May 1;27(9):2416-2423. doi: 10.1158/1078-0432.CCR-20-3853. Epub 2021 Feb 9. Clin Cancer Res. 2021. PMID: 33563636 Free PMC article. Review.
Phase I. Trial of irinotecan plus carboplatin in two dose schedules.
Jones SF, Burris HA 3rd, Hainsworth JD, Yardley DA, Raefsky EA, Miranda FT, Kuzur ME, Willcutt NT, White MB, Greco FA. Jones SF, et al. Oncology (Williston Park). 2003 May;17(5 Suppl 5):36-40. Oncology (Williston Park). 2003. PMID: 12800605 Review.
106 results